

Part

5 入院診療(特別な対応)

5-1 妊産婦, 授乳婦への対応

●参考文献

1. Committee on Obstetric Practice. Committee Opinion No. 723 : Guidelines for Diagnostic Imaging During Pregnancy and Lactation. *Obstet Gynecol* 2017 ; 130 : e210-6.
PMID : 28937575 **ガイドライン**
2. Patel SJ, et al. Imaging the pregnant patient for nonobstetric conditions : algorithms and radiation dose considerations. *Radiographics* 2007 ; 27 : 1705-22.
PMID : 18025513
3. Themblay E, et al. Quality Initiatives : guidelines for use of medical imaging during pregnancy and lactation. *Radiographics* 2012 ; 32 : 897-911.
PMID 22403117 **ガイドライン**
4. Ray JG, et al. Association Between MRI Exposure During Pregnancy and Fetal and Childhood Outcomes. *JAMA* 2016 ; 316 : 952-61. PMID : 27599330
5. Greer IA. CLINICAL PRACTICE. Pregnancy Complicated by Venous Thrombosis. *N Engl J Med* 2015 ; 373 : 540-7. PMID : 26244307
6. 日本産科婦人科学会ほか. 産婦人科診療ガイドライン—産科編 2017. CQ104-5 授乳中に使用している医薬品の児への影響について尋ねられたら? 2017 : 87-9.
ガイドライン
7. 佐藤孝道ほか編. 実践 妊娠と薬 第2版—10,000例の相談事例とその情報. 東京 : じほう, 2010.
8. Ystrom E, et al. Prenatal Exposure to Acetaminophen and Risk of ADHD. *Pediatrics* 2017 ; 140 : e20163840. PMID : 29084830

●リンクページ

- DailyMed <<https://dailymed.nlm.nih.gov/dailymed/index.cfm>>
- 国立成育医療センター 妊娠と薬情報センター「授乳中の薬(一覧表)」<https://www.ncchd.go.jp/kusuri/news_med/druglist.html>
- Drugs and Lactation Database (LactMed) <<https://toxnet.nlm.nih.gov/newtoxnet/lactmed.htm>>

5-2 非心臓手術における術前評価

●参考文献

1. Racz J, et al. Elective and emergency abdominal surgery in patients 90 years of age or older. *Can J Surg* 2012 ; 55 : 322-8. PMID : 22992421
2. Kristensen SD, et al. 2014 ESC/ESA Guidelines on non-cardiac surgery : cardiovascular assessment and management : The Joint Task Force on non-cardiac surgery :

- cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). *Eur Heart J* 2014 ; 35 : 2383-431. PMID : 25086026 **ガイドライン**
3. Chow WB, et al. Optimal preoperative assessment of the geriatric surgical patient : a best practices guideline from the American College of Surgeons National Surgical Quality Improvement Program and the American Geriatrics Society. *J Am Coll Surg* 2012 ; 215 : 453-66. PMID : 22917646 **ガイドライン**
 4. Lin HS, et al. Frailty and post-operative outcomes in older surgical patients : a systematic review. *BMC Geriatr* 2016 ; 16 : 157. PMID : 27580947
 5. Partridge JSL, et al. Randomized clinical trial of comprehensive geriatric assessment and optimization in vascular surgery. *Br J Surg* 2017 ; 104 : 679-87. PMID : 28198997
 6. Tonnesen H, et al. Preoperative alcoholism and postoperative morbidity. *Br J Surg* 1999 ; 86 : 869-74. PMID : 10417555
 7. Feely MA, et al. Preoperative testing before noncardiac surgery : guidelines and recommendations. *Am Fam Physician* 2013 ; 87 : 414-8. PMID : 23547574 **ガイドライン**
 8. Johansson T, et al. Effectiveness of non-cardiac preoperative testing in non-cardiac elective surgery : a systematic review. *Br J Anaesth* 2013 ; 110 : 926-39. PMID : 23578861
 9. Karthikeyan G, et al. Is a pre-operative brain natriuretic peptide or N-terminal pro-B-type natriuretic peptide measurement an independent predictor of adverse cardiovascular outcomes within 30 days of noncardiac surgery? A systematic review and meta-analysis of observational studies. *J Am Coll Cardiol* 2009 ; 54 : 1599-606. PMID : 19833258
 10. Qaseem A, et al. Risk assessment for and strategies to reduce perioperative pulmonary complications for patients undergoing noncardiothoracic surgery : a guideline from the American College of Physicians. *Ann Intern Med* 2006 ; 144 : 575-80. PMID : 16618955 **ガイドライン**
 11. Smetana GW. Postoperative pulmonary complications : an update on risk assessment and reduction. *Cleve Clin J Med* 2009 ; 76 Suppl 4 : S60-5. PMID : 19880838
 12. Friedman LS. The risk of surgery in patients with liver disease. *Hepatology* 1999 ; 29 : 1617-23. PMID : 10347099
 13. Rai R, et al. Surgery in a patient with liver disease. *J Clin Exp Hepatol* 2012 ; 2 : 238-46. PMID : 25755440
 14. Abbas N, et al. Perioperative Care of Patients With Liver Cirrhosis : A Review. *Health Serv Insights* 2017 ; 10 : 1178632917691270. PMID : 28469455
 15. Devereaux PJ, et al. Aspirin in patients undergoing noncardiac surgery. *N Engl J Med* 2014 ; 370 : 1494-503. PMID : 24679062
 16. Graham MM, et al. Aspirin in Patients With Previous Percutaneous Coronary Intervention Undergoing Noncardiac Surgery. *Ann Intern Med* 2018 ; 168 : 237-44. PMID : 29132159
 17. Raval AN, et al. Management of Patients on Non-Vitamin K Antagonist Oral Anti-coagulants in the Acute Care and Periprocedural Setting : A Scientific Statement From the American Heart Association. *Circulation* 2017 ; 135 : e604-33. PMID : 28167634

18. Oprea AD, et al. Perioperative management of antiplatelet therapy. Br J Anaesth 2013 ; 111 Suppl 1 : i3-17. PMID : 24335397
19. Banerjee S, et al. Use of Antiplatelet Therapy/DAPT for Post-PCI Patients Undergoing Noncardiac Surgery. J Am Coll Cardiol 2017 ; 69 : 1861-70. PMID : 28385315
20. Valgimigli M, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS : The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018 ; 39 : 213-60. PMID : 28886622
21. Childers CP, et al. Perioperative management of antiplatelet therapy in patients undergoing non-cardiac surgery following coronary stent placement : a systematic review. Syst Rev 2018 ; 7 : 4. PMID : 29321066
22. Douketis JD, et al. Perioperative management of antithrombotic therapy : Anti-thrombotic Therapy and Prevention of Thrombosis, 9th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012 ; 141 (2 Suppl) : e326S-50S. PMID : 22315266 **ガイドライン**
23. Mans CM, et al. Postoperative outcomes following preoperative inspiratory muscle training in patients undergoing cardiothoracic or upper abdominal surgery : a systematic review and meta analysis. Clin Rehabil 2015 ; 29 : 426-38. PMID : 25160007
24. Dhataria K, et al. NHS Diabetes guideline for the perioperative management of the adult patient with diabetes. Diabet Med 2012 ; 29 : 420-33. PMID : 22288687 **ガイドライン**
25. Australian Diabetes Society. Peri-operative Diabetes Management Guidelines. July 2012. <<https://diabetessociety.com.au/documents/PerioperativeDiabetesManagementGuidelinesFINALCleanJuly2012.pdf>> **ガイドライン**
26. Coursin DB, et al. Corticosteroid supplementation for adrenal insufficiency. JAMA 2002 ; 287 : 236-40. PMID : 11779267
27. Khazen BF, et al. The use of a perioperative supra-physiological dose of glucocorticoid is not supported by evidence — a systematic review. Dan Med J 2018 ; 65 : A5488. PMID : 29886882
28. Loza E, et al. A systematic review on the optimum management of the use of methotrexate in rheumatoid arthritis patients in the perioperative period to minimize perioperative morbidity and maintain disease control. Clin Exp Rheumatol 2009 ; 27 : 856-62. PMID : 19917174

●参考リンク

- Post-operative Mortality Risk in Patients with Cirrhosis (肝機能低下症例における周術期死亡率の計算) <<https://www.mayoclinic.org/medical-professionals/transplantmedicine/calculators/post-operative-mortality-risk-in-patients-with-cirrhosis/itt-20434721>>

5-3 漢方の活用方法と副作用

●参考文献

1. Hyde AJ, et al. Herbal medicine for management of the behavioural and psychological symptoms of dementia (BPSD) : A systematic review and meta-analysis. J Psy-

- chopharmacol 2017 ; 31 : 169-83. PMID : 27899689
2. Matsunaga S, et al. Yokukansan in the Treatment of Behavioral and Psychological Symptoms of Dementia : An Updated Meta-Analysis of Randomized Controlled Trials. *J Alzheimers Dis* 2016 ; 54 : 635-43. PMID : 27497482
 3. Furukawa K, et al. Randomized double-blind placebo-controlled multicenter trial of Yokukansan for neuropsychiatric symptoms in Alzheimer's disease. *Geriatr Gerontol Int* 2017 ; 17 : 211-8. PMID : 26711658
 4. Cheng CW, et al. Efficacy of a Chinese herbal proprietary medicine (Hemp Seed Pill) for functional constipation. *Am J Gastroenterol* 2011 ; 106 : 120-9. PMID : 21045817
 5. Numata T, et al. Cellular mechanism for herbal medicine Junchoto to facilitate intestinal Cl⁻/water secretion that involves cAMP-dependent activation of CFTR. *J Nat Med* 2018 ; 72 : 694-705. PMID : 29569221
 6. Harada Y, et al. Mashiningan Improves Opioid-Induced Constipation in Rats by Activating Cystic Fibrosis Transmembrane Conductance Regulator Chloride Channel. *J Pharmacol Exp Ther* 2017 ; 362 : 78-84. PMID : 28465373
 7. 日本消化器病学会関連研究会 慢性便秘の診断・治療研究会. 慢性便秘症診療ガイドライン 2017. 東京 : 南江堂, 2017. **ガイドライン**
 8. 熊田 卓ほか. Tj-68 ツムラ芍薬甘草湯の筋痙攣 (肝硬変に伴うもの) に対するプラセボ対照二重盲検群間比較試験. *臨医薬* 1999 ; 15 : 499-523.
 9. 牧 綾子ほか. ツムラ芍薬甘草湯エキス顆粒 (医療用) の副作用発現頻度調査. *診断と治療* 2016 ; 104 : 947-58.
 10. Yoshida T, et al. The efficacy of prophylactic Shakuyaku-Kanzo-to for myalgia and arthralgia following carboplatin and paclitaxel combination chemotherapy for non-small cell lung cancer. *Support Care Cancer* 2009, 17 (3) : 315-320.
 11. Ishizuka M, et al. Perioperative Administration of Traditional Japanese Herbal Medicine Daikenchuto Relieves Postoperative Ileus in Patients Undergoing Surgery for Gastrointestinal Cancer : A Systematic Review and Meta-analysis. *Anticancer Res* 2017 ; 37 : 5967-74. PMID : 29061775
 12. Hoshino N, et al. Daikenchuto for reducing postoperative ileus in patients undergoing elective abdominal surgery. *Cochrane Database Syst Rev* 2018 ; 4 : CD012271. PMID : 29619778
 13. Mori K, et al. Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer. *Cancer Chemother Pharmacol* 2003 ; 51 : 403-6. PMID : 12687289
 14. Matsuda C, et al. Double-blind, placebo-controlled, randomized phase II study of TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositis. *Cancer Chemother Pharmacol* 2015 ; 76 : 97-103. PMID : 25983022
 15. Aoyama T, et al. Double-blind, placebo-controlled, randomized phase II study of TJ-14 (hangeshashinto) for gastric cancer chemotherapy-induced oral mucositis. *Cancer Chemother Pharmacol* 2014 ; 73 : 1047-54. PMID : 24652604
 16. Ohno T, et al. Rikkunshito, a traditional Japanese medicine, suppresses cisplatin-induced anorexia in humans. *Clin Exp Gastroenterol* 2011 ; 4 : 291-6. PMID : 22235173
 17. Ohnishi S, et al. Additive effect of rikkunshito, an herbal medicine, on chemothera-

- py-induced nausea, vomiting, and anorexia in uterine cervical or corpus cancer patients treated with cisplatin and paclitaxel: results of a randomized phase II study (JORTC KMP-02). *J Gynecol Oncol* 2017; 28: e44. PMID: 28657216
18. Harada T, et al. Rikkunshito for Preventing Chemotherapy-Induced Nausea and Vomiting in Lung Cancer Patients: Results from 2 Prospective, Randomized Phase 2 Trials. *Front Pharmacol* 2018; 8: 972. PMID: 29387008
 19. Kono T, et al. Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, doubleblind, placebocontrolled trial of goshajinkigan to prevent oxaliplatininduced neuropathy. *Cancer Chemother Pharmacol* 2013; 72: 1283-90. PMID: 24121454
 20. Oki E, et al. Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study. *Int J Clin Oncol* 2015; 20: 767-75. PMID: 25627820
 21. Kuriyama A, et al. Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. *Support Care Cancer* 2018; 26: 1051-9. PMID: 29280005
 22. Hoshino N, et al. Goshajinkigan for reducing chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. *Int J Clin Oncol* 2018; 23: 434-42. PMID: 29270698
 23. Fujita N, et al. An extract of the root of *Lithospermum erythrorhizon* accelerates wound healing in diabetic mice. *Biol Pharm Bull* 2003; 26: 329-35. PMID: 12612442
 24. Na-Bangchang K, et al. Exploratory, Phase II Controlled Trial of Shiunko Ointment Local Application Twice a Day for 4 Weeks in Ethiopian Patients with Localized Cutaneous Leishmaniasis. *Evid Based Complement Alternat Med* 2016; 2016: 5984709. PMID: 27195014
 25. Yoshino T, et al. Risk Factors for Pseudoaldosteronism with Rhabdomyolysis Caused by Consumption of Drugs Containing Licorice and Differences Between Incidence of These Conditions in Japan and Other Countries: Case Report and Literature Review. *J Altern Complement Med* 2014; 20: 516-20. PMID: 24620820
 26. Yoshino T, et al. Elevated direct bilirubin-Possible predictors for pseudoaldosteronism: Case-control study. *Traditional and Kampo Medicine* 2016; 2: 174-6.
 27. Komatsu A, et al. Risk factors associated with pseudoaldosteronism in patients with chronic hepatitis: A retrospective cohort study. *Basic Clin Pharmacol Toxicol* 2019; 124: 607-14. PMID: 30471199
 28. Ploeger B, et al. A human physiologically-based model for glycyrrhizic acid, a compound subject to presystemic metabolism and enterohepatic cycling. *Pharm Res* 2000; 17: 1516-25. PMID: 11303962

● 推奨文献

- 樫尾明彦. 先生, 漢方を鍼灸を試してみたいんですけど……患者さんにいわれて困ったときに読む本. 東京: 南山堂, 2015.
- 渡辺賢治. マトリックスでわかる! 漢方薬使い分けの極意. 東京: 南江堂, 2013.
- 樫尾明彦ほか. スーパー★ジェネラリストに必要なモダン・カンボウ クリニカル・パール集&総合医の実体験. 東京: 新興医学出版社, 2014.
- 日本東洋医学会 EBM 委員会. 漢方薬治療エビデンスレポート 2013—402 の RCT—

(EKAT 2013) (Evidence reports of Kampo Treatment) <<http://www.jsom.or.jp/medical/ebm/er/pdf/EKATJ2013.pdf>>

◎参考リンク

- 日本東洋医学会 EBM 委員会. 「漢方治療エビデンスレポート」<<http://www.jsom.or.jp/medical/ebm/>>
- 日本東洋医学会 EBM 委員会. 「漢方製剤の記載を含む診療ガイドライン」<<http://www.jsom.or.jp/medical/ebm/>> **ガイドライン**

5-4 向精神薬

◎参照文献

1. Morgan K, et al. Anxiety caused by a short-life hypnotic. *Br Med J (Clin Res Ed)* 1982; 284: 942. PMID: 6121606
2. Wagner AK, et al. Benzodiazepine use and hip fractures in the elderly: who is at greatest risk? *Arch Intern Med* 2004; 164: 1567-72. PMID: 15277291
3. Sun GQ, et al. Benzodiazepines or related drugs and risk of pneumonia: A systematic review and meta-analysis. *Int J Geriatr Psychiatry* 2019; 34: 513-21. PMID: 30623504
4. Hampton LM, et al. Emergency department visits by adults for psychiatric medication adverse events. *JAMA Psychiatry* 2014; 71: 1006-14. PMID: 25006837
5. Glass J, et al. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. *BMJ* 2005; 331: 1169. PMID: 16284208
6. Weich S, et al. Effect of anxiolytic and hypnotic drug prescriptions on mortality hazards: retrospective cohort study. *BMJ* 2014; 348: g1996. PMID: 24647164
7. 富田真幸ほか. 薬物療法 抗不安薬. *臨精医* 2006; 35 (増刊): 354-67.
8. Yasui-Furukori N, et al. Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects. *Eur J Clin Pharmacol* 2007; 63: 51-6. PMID: 17124578
9. Buckley NA, et al. Serotonin syndrome. *BMJ* 2014; 348: g1626. PMID: 24554467
10. Beach SR, et al. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. *J Clin Psychiatry* 2014; 75: e441-9. PMID: 24922496
11. Birks JS, et al. Donepezil for dementia due to Alzheimer's disease. *Cochrane Database Syst Rev* 2018; 6: CD001190. PMID: 29923184
12. Matsunaga S, et al. Cholinesterase Inhibitors for Lewy Body Disorders: A Meta-Analysis. *Int J Neuropsychopharmacol* 2015; 19: pyv086. PMID: 26221005
13. Stinton C, et al. Pharmacological Management of Lewy Body Dementia: A Systematic Review and Meta-Analysis. *Am J Psychiatry* 2015; 172: 731-42. PMID: 26085043
14. 日本神経学会. 認知症疾患診療ガイドライン 2017. 各論 第7章 Lewy 小体型認知症. <https://www.neurology-jp.org/guidelinem/deg1/deg1_2017_07.pdf> **ガイドライン**
15. McShane R, et al. Memantine for dementia. *Cochrane Database Syst Rev* 2019; 3: CD003154. PMID: 30891742
16. Farrimond LE, et al. Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review. *BMJ Open* 2012; 2. PMID: 22689908

17. Ray WA, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. *N Engl J Med* 2009 ; 360 : 225-35. PMID : 19144938
18. Gill SS, et al. Antipsychotic drug use and mortality in older adults with dementia. *Ann Intern Med* 2007 ; 146 : 775-86. PMID : 17548409
19. Inada T, et al. Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol. *Schizophr Res* 2002 ; 57 : 227-38. PMID : 12223254
20. Muench J, et al. Adverse effects of antipsychotic medications. *Am Fam Physician* 2010 ; 81 : 617-22. PMID : 20187598
21. Stroup TS, et al. Management of common adverse effects of antipsychotic medications. *World Psychiatry* 2018 ; 17 : 341-56. PMID : 30192094
22. Poyurovsky M. Acute antipsychotic-induced akathisia revisited. *Br J Psychiatry* 2010 ; 196 : 89-91. PMID : 20118449
23. Boyer EW, et al. The serotonin syndrome. *N Engl J Med* 2005 ; 352 : 1112-20. PMID : 15784664
24. Sim SS, et al. Ocular Flutter in the Serotonin Syndrome. *N Engl J Med* 2016 ; 375 : e38. PMID : 27806222
25. Perry PJ, et al. Serotonin syndrome vs neuroleptic malignant syndrome : a contrast of causes, diagnoses, and management. *Ann Clin Psychiatry* 2012 ; 24 : 155-62. PMID : 22563571
26. 西嶋康一. セロトニン症候群. *日臨* 2012 ; 70 : 616-9.
27. Huang V, et al. Risk of serotonin syndrome with concomitant administration of linezolid and serotonin agonists. *Pharmacotherapy* 2006 ; 26 : 1784-93. PMID : 17125439
28. Dunkley EJ, et al. The Hunter Serotonin Toxicity Criteria : simple and accurate diagnostic decision rules for serotonin toxicity. *QJM* 2003 ; 96 : 635-42. PMID : 12925718
29. Ables AZ, et al. Prevention, recognition, and management of serotonin syndrome. *Am Fam Physician* 2010 ; 81 : 1139-42. PMID : 20433130
30. 厚生労働省. 重篤副作用疾患別対応マニュアル. セロトニン症候群. 平成 22 年 3 月. <<http://www.mhlw.go.jp/topics/2006/11/dl/tp1122-1j13.pdf>>
31. 助川鶴平. 抗精神病薬多剤投与の是正に向けて. *精神誌* 2012 ; 114 : 696-701.

5-5 輸血学

◎ 参考文献

1. 米村雄士ほか. 科学的根拠に基づいた赤血球製剤の使用ガイドライン (改訂第 2 版). *日輸血細胞治療会誌* 2018 ; 64 : 688-99. <https://minds.jcqh.or.jp/docs/gl_pdf/G0001196/4/red_blood_cell_products.pdf> **ガイドライン**
2. Carson JL, et al. Clinical Practice Guidelines From the AABB : Red Blood Cell Transfusion Thresholds and Storage. *JAMA* 2016 ; 316 : 2025-35. PMID : 27732721 **ガイドライン**
3. 高見昭吉ほか. 科学的根拠に基づいた血小板製剤の使用ガイドライン : 2019 年改訂版. *日輸血細胞治療会誌* 2019 ; 65 : 544-61. <https://www.jstage.jst.go.jp/article/jjtc/65/3/65_544/_pdf/-char/ja> **ガイドライン**
4. Kaufman RM, et al. Platelet transfusion : a clinical practice guideline from the AABB. *Ann Intern Med* 2015 ; 162 : 205-13. PMID : 25383671 **ガイドライン**

5. Estcourt LJ, et al. Guidelines for the use of platelet transfusions. *Br J Haematol* 2017; 176: 365-94. PMID: 28009056 **ガイドライン**
6. 日本輸血・細胞治療学会. 洗浄・置換血小板の適応およびその調剤の指針 (Version V) 2016年4月27日改定. <<http://yuketsu.jstmct.or.jp/wp-content/uploads/2016/05/96cdc072ad4370a5c012729b39e465cb.pdf>>
7. 石田 明. 洗浄・置換血小板の特徴と適応. *日輸血細胞治療会誌* 2018; 64: 8-15. <https://www.jstage.jst.go.jp/article/jjtc/64/1/64_8/_pdf/-char/ja>
8. 松下 正ほか. 科学的根拠に基づいた新鮮凍結血漿 (FFP) の使用ガイドライン [改訂第2版]. *日輸血細胞治療会誌* 2019; 65: 525-37. <https://www.jstage.jst.go.jp/article/jjtc/65/3/65_525/_pdf/-char/ja> **ガイドライン**
9. Roback JD, et al. Evidence-based practice guidelines for plasma transfusion. *Transfusion* 2010; 50: 1227-39. PMID: 20345562 **ガイドライン**
10. Green L, et al. British Society of Haematology Guidelines on the spectrum of fresh frozen plasma and cryoprecipitate products: their handling and use in various patient groups in the absence of major bleeding. *Br J Haematol* 2018; 181: 54-67. PMID: 29527654 **ガイドライン**
11. Holland LL, et al. Fresh frozen plasma is ineffective for correcting minimally elevated international normalized ratios. *Transfusion* 2005; 45: 1234-5. PMID: 15987373
12. 岡崎 仁ほか. 科学的根拠に基づいた輸血有害事象対応ガイドライン. *日輸血細胞治療会誌* 2019; 65: 1-9. <https://www.jstage.jst.go.jp/article/jjtc/65/1/65_1/_pdf/-char/ja> **ガイドライン**
13. Delaney M, et al. Transfusion reactions: prevention, diagnosis, and treatment. *Lancet* 2016; 388: 2825-36. PMID: 27083327
14. 日本輸血・細胞治療学会 ヘモビジュランス小委員会. 輸血製剤副反応動向—2017—. 令和元年7月1日. <<http://yuketsu.jstmct.or.jp/wp-content/uploads/2019/07/88ca0abdf1a074260e3792999ca832c4.pdf>>
15. Panch SR, et al. Hemolytic Transfusion Reactions. *N Engl J Med* 2019; 381: 150-62. PMID: 31291517
16. Vlaar APJ, et al. Transfusion-related acute lung injury: a clinical review. *Lancet* 2013; 382: 984-94. PMID: 23642914
17. Skeate RC, et al. Distinguishing between transfusion related acute lung injury and transfusion associated circulatory overload. *Curr Opin Hematol* 2007; 14: 682-7. PMID: 17898575
18. Shander A, et al. Management of anemia in patients who decline blood transfusion. *Am J Hematol* 2018; 93: 1183-91. PMID: 30033541
19. Resar LMS, et al. Bloodless medicine: current strategies and emerging treatment paradigms. *Transfusion* 2016; 56: 2637-47. PMID: 27473810

5-6 悪性腫瘍総論

◎参考文献

1. Choosing Wisely. ASCO. Ten things Physicians and Patients should question. Released April 4, 2012 (1-5) and October 29, 2013 (6-10). <<http://www.choosingwisely.org/societies/american-society-of-clinical-oncology/>>
2. Mohammed N, et al. Rapid disease progression with delay in treatment of non-

- small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 2011 ; 79 : 466-72.
PMID : 20471184
3. Eisenhauer EA, et al. New response evaluation criteria in solid tumours : revised RECIST guideline (version 1.1). *Eur J Cancer* 2009 ; 45 : 228-47.
PMID : 19097774 **ガイドライン**
 4. Clinical Research Resource HUB. Clinical Trial Protocol Development. <<https://hub.ucsf.edu/protocol-development>>
 5. NCCN Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer Version 4. 2021. <<https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450>> **ガイドライン**
 6. Warr J, et al. Baseline blood work before initiation of chemotherapy : what is safe in the real world? *J Oncol Pract* 2013 ; 9 : e182-5. PMID : 24045345
 7. NCCN Clinical Practice Guidelines in Oncology. Older Adult Oncology Version 1. 2020. <<https://www.nccn.org/guidelines/guidelines-detail?category=4&id=1452>> **ガイドライン**
 8. Van Poznak CH, et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. *J Clin Oncol* 2011 ; 29 : 1221-7. PMID : 21343561 **ガイドライン**
 9. Yarom N, et al. Medication-Related Osteonecrosis of the Jaw : MASCC/ISOO/ASCO Clinical Practice Guideline. *J Clin Oncol* 2019 ; 37 : 2270-90.
PMID : 31329513 **ガイドライン**
 10. Gardner A, et al. Randomized comparison of cooked and noncooked diets in patients undergoing remission induction therapy for acute myeloid leukemia. *J Clin Oncol* 2008 ; 26 : 5684-8. PMID : 18955453
 11. Rubin LG, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. *Clin Infect Dis* 2014 ; 58 : e44-100. PMID : 24311479 **ガイドライン**
 12. NCCN Clinical Practice Guidelines in Oncology. Central Nervous System Cancers Version 5. 2020. <<https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1425>> **ガイドライン**
 13. NCCN Clinical Practice Guidelines in Oncology. Small Cell Lung Cancer Version 3. 2021. <<https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1462>> **ガイドライン**
 14. NCCN Clinical Practice Guidelines in Oncology. Testicular Cancer Version 2. 2021. <<https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1468>> **ガイドライン**
 15. NCCN Clinical Practice Guidelines in Oncology. Palliative Care Version 2. 2021. <<https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1454>> **ガイドライン**
 16. Ferrell BR, et al. Integration of Palliative Care Into Standard Oncology Care : American Society of Clinical Oncology Clinical Practice Guideline Update. *J Clin Oncol* 2017 ; 35 : 96-112. PMID : 28034065 **ガイドライン**
 17. Temel JS, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. *N Engl J Med* 2010 ; 363 : 733-42. PMID : 20818875
 18. Bernacki RE, et al. Communication about serious illness care goals : a review and synthesis of best practices. *JAMA Intern Med* 2014 ; 174 : 1994-2003. PMID : 25330167

●参考リンク

- 日本臨床腫瘍研究グループ (Japan Clinical Oncology Group : JCOG) <<http://www.jcog.jp/>>
- NCCN ガイドライン 日本語版 <<http://www.tri-kobe.org/nccn/index.html>> ガイドライン
- NCCN Clinical Practice Guidelines in Oncology <https://www.nccn.org/guidelines/category_1> ガイドライン
- ASCO Clinical Practice Guidelines <<https://www.asco.org/research-guidelines/quality-guidelines/guidelines>> ガイドライン
- 日本乳癌学会 <<http://jbcg.gr.jp>>
- 日本肺癌学会 <<https://www.haigan.gr.jp>>
- 日本泌尿器科学会 <<https://www.urol.or.jp>>
- 日本胃癌学会 <<http://www.jgca.jp>>
- 日本婦人科腫瘍学会 <<https://jsco.or.jp>>
- 日本癌治療学会 <<http://www.jsco.or.jp/jpn/>>
- 日本臨床腫瘍学会 <<http://www.jsmo.or.jp>>

5-7 緩和医療

●参照文献

1. Cook D, et al. Dying with dignity in the intensive care unit. *N Engl J Med* 2014; 370 : 2506-14. PMID : 24963569
2. Schapira L. Communications by professionals in palliative care. *Clin Geriatr Med* 2015 ; 31 : 231-43. PMID : 25920058 推奨文献
3. Kelley AS, et al. Palliative Care for the Seriously Ill. *N Engl J Med* 2015 ; 373 : 747-55. PMID : 26287850
4. Clayton JM, et al. Clinical practice guidelines for communicating prognosis and end-of-life issues with adults in the advanced stages of a life-limiting illness, and their caregivers. *Med J Aust* 2007 ; 186 : S77-105. PMID : 17727340 ガイドライン
5. Bell D, et al. Care of Geriatric Patients with Advanced Illnesses and End-of-Life Needs in the Emergency Department. *Clin Geriatr Med* 2018 ; 34 : 453-67. PMID : 30031427 推奨文献
6. Smith TJ. Symptom management in the older adult : 2015 update. *Clin Geriatr Med* 2015 ; 31 : 155-75. PMID : 25920053 推奨文献
7. Alexander K, et al. Palliative Care and Symptom Management in Older Patients with Cancer. *Clin Geriatr Med* 2016 ; 32 : 45-62. PMID : 26614860
8. von Gunten CF, et al. Treatment of non-pain-related symptoms. *Cancer J* 2013 ; 19 : 397-404. PMID : 24051612
9. Albert RH. End-of-Life Care : Managing Common Symptoms. *Am Fam Physician* 2017 ; 95 : 356-61. PMID : 28318209
10. Qaseem A, et al. Evidence-based interventions to improve the palliative care of pain, dyspnea, and depression at the end of life : a clinical practice guideline from the American College of Physicians. *Ann Intern Med* 2008 ; 148 : 141-6. PMID : 18195338 ガイドライン 推奨文献
11. 大谷弘行. 症状マネジメント : 精神症状 : 不安, 抑うつ, せん妄の評価と治療. *Hospital-*

- ist 2014 ; 2 : 935-45.
12. Locke AB, et al. Diagnosis and management of generalized anxiety disorder and panic disorder in adults. *Am Fam Physician* 2015 ; 91 : 617-24. PMID : 25955736
 13. Davies AN. A comparison of artificial saliva and chewing gum in the management of xerostomia in patients with advanced cancer. *Palliat Med* 2000 ; 14 : 197-203. PMID : 10858827
 14. MASCC/ISOO. がん治療に伴う粘膜障害に対するエビデンスに基づいた臨床診療ガイドライン. 2014年11月7日一部修正 (日本語訳 2014年11月8日一部修正). <<https://www.mascc.org/assets/Guidelines-Tools/guidelines%20summary%207nov2014-japanese.pdf>> **ガイドライン**
 15. American Geriatrics Society feeding tubes in advanced dementia position statement. *J Am Geriatr Soc* 2014 ; 62 : 1590-3. PMID : 25039796
 16. Morita T, et al. Artificial hydration therapy, laboratory findings, and fluid balance in terminally ill patients with abdominal malignancies. *J Pain Symptom Manage* 2006 ; 31 : 130-9. PMID : 16488346
 17. Lanuke K, et al. Hydration management at the end of life. *J Palliat Med* 2004 ; 7 : 257-63. PMID : 15130203
 18. Raijmakers NJ, et al. Artificial nutrition and hydration in the last week of life in cancer patients. A systematic literature review of practices and effects. *Ann Oncol* 2011 ; 22 : 1478-86. PMID : 21199887
 19. Larkin PJ, et al. The management of constipation in palliative care : clinical practice recommendations. *Palliat Med* 2008 ; 22 : 796-807. PMID : 18838491
 20. 上島邦彦. 便秘へのアプローチ. *Hospitalist* 2017 ; 5 : 737-49.

●参考リンク

- 聖隷三方原病院 症状緩和ガイド. <http://www.seirei.or.jp/mikatahara/doc_kanwa/index.html>

5-8 感染症に対する原則

●参考文献

1. Weinstein L. Common sense (clinical judgment) in the diagnosis and antibiotic therapy of etiologically undefined infections. *Pediatr Clin North Am* 1968 ; 15 : 141-56. PMID : 5689011
2. Hindler JF, et al. Analysis and presentation of cumulative antibiograms : a new consensus guideline from the Clinical and Laboratory Standards Institute. *Clin Infect Dis* 2007 ; 44 : 867-73. PMID : 17304462 **ガイドライン**
3. Paul M, et al. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients : systematic review and meta-analysis of randomised trials. *BMJ* 2004 ; 328 : 668-81. PMID : 14996699
4. Moellering RC Jr, et al. Studies on antibiotic synergism against enterococci. I. Bacteriologic studies. *J Lab Clin Med* 1971 ; 77 : 821-8. PMID : 4997545
5. Paul M, et al. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. *Antimicrob Agents Chemother* 2010 ; 54 : 4851-63. PMID : 20733044

6. Micek ST, et al. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria : a retrospective analysis. *Antimicrob Agents Chemother* 2010 ; 54 : 1742-8. PMID : 20160050
7. Nahum GG, et al. Antibiotic use in pregnancy and lactation : what is and is not known about teratogenic and toxic risks. *Obstet Gynecol* 2006 ; 107 : 1120-38. PMID : 16648419
8. Moellering RC Jr. Antimicrobial agents in pregnancy and the postpartum period. *Clin Obstet Gynecol* 1989 ; 22 : 277.
9. Myrrey TS, et al. Pediatric Uses of Fluoroquinolone Antibiotics. *Pediatr Ann* 2007 ; 36 : 336-42. PMID : 17727139
10. Weinstein L, et al. Host determinants of response to antimicrobial agents. *N Engl J Med* 1968 ; 279 : 524-31. PMID : 4876471
11. Davey PG. Pharmacokinetics in liver disease. *J Antimicrob Chemother* 1988 ; 21 : 1-5. PMID : 3281925
12. Craig WA. Pharmacokinetic/pharmacodynamic parameters : rationale for antibacterial dosing of mice and men. *Clin Infect Dis* 1998 ; 26 : 1-10 ; quiz 11-2. PMID : 9455502
13. Tamma PD, et al. Antimicrobial stewardship. *Infect Dis Clin North Am* 2011 ; 25 : 245-60. PMID : 21316003
14. Siegel JD, et al. 2007. 2007 Guideline for Isolation Precautions : Preventing Transmission of Infectious Agents in Healthcare Settings. *Am J Infect Control* 2007 ; 35 (10 Suppl 2) : S65-164. PMID : 18068815 **ガイドライン**

● 推奨文献

- Eliopoulos GM, et al. Principles of Anti-Infective Therapy. In : Bennett JE, et al. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 8th ed. Philadelphia : Elsevier, 2014 : 224-34.
- 青木 眞. レジデントのための感染症診療マニュアル第3版. 東京 : 医学書院. 2015.
- 前崎繁文ほか. 臨床感染症ブックレット 2巻. エンピリック治療の抗菌薬, 確定治療の抗菌薬を選択する. 東京 : 文光堂, 2010.
- Bartlett JG , et al. Johns Hopkins ABX Guide Diagnosis and Treatment of Infectious Diseases 2012. 3rd ed. Baltimore : Johns Hopkins Medicine, 2011.
- Gilbert DN, et al (eds). The Sanford Guide to Antimicrobial Therapy 2016. 46th ed. Ingram. Antimicrobial Therapy, 2016.
- 国立大学附属病院感染対策協議会編. 病院感染対策ガイドライン 改訂第2版. 東京 : じほう. 2015. **ガイドライン**

● リンクページ

- 国立成育医療研究センター 妊娠と薬情報センター <https://www.ncchd.go.jp/kusuri/news_med/login.html>
- 抗菌薬 TDM ガイドライン. Executive summary (平成 24 年 8 月 1 日更新). TDM (Therapeutic Drug Monitoring) <http://www.chemotherapy.or.jp/guideline/tdm_executive-summary.pdf>
- CDC. The Core Elements of Hospital Antibiotic Stewardship Programs. <<http://www.cdc.gov/getsmart/healthcare/pdfs/core-elements.pdf>>

5-9 耐性菌

◎参照文献

1. Matsumura Y, et al. Multicenter retrospective study of cefmetazole and flomoxef for treatment of extended-spectrum- β -lactamase-producing *Escherichia coli* bacteremia. *Antimicrob Agents Chemother* 2015 ; 59 : 5107-13. PMID : 26100708
2. Doi A, et al. The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae. *Int J Infect Dis* 2013 ; 17 : e159-63. PMID : 23140947
3. Rodríguez-Baño J, et al. Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae. *Clin Microbiol Rev* 2018 ; 31 : e00079-17. PMID : 29444952
4. Choi SH, et al. Emergence of antibiotic resistance during therapy for infections caused by Enterobacteriaceae producing AmpC beta-lactamase : implications for antibiotic use. *Antimicrob Agents Chemother* 2008 ; 52 : 995-1000. PMID : 18086837
5. Christie MJ, et al. 6-Hydroxydopamine and excitotoxin lesions of medial prefrontal cortex fail to affect schedule-induced drinking in the rat. *Behav Brain Res* 1986 ; 19 : 183-6. PMID : 3083838
6. Tamma PD, et al. The use of cefepime for treating AmpC β -lactamase-producing Enterobacteriaceae. *Clin Infect Dis* 2013 ; 57 : 781-8. PMID : 23759352
7. Horcajada JP, et al. Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant *Pseudomonas aeruginosa* Infections. *Clin Microbiol Rev* 2019 ; 32 : e00031-19. PMID : 31462403
8. Piperaki ET, et al. Carbapenem-resistant *Acinetobacter baumannii* : in pursuit of an effective treatment. *Clin Microbiol Infect* 2019 ; 25 : 951-7. PMID : 30914347
9. Logan LK, et al. The Epidemiology of Carbapenem-Resistant Enterobacteriaceae : The Impact and Evolution of a Global Menace. *J Infect Dis* 2017 ; 215 (suppl_1) : S28-36. PMID : 28375512
10. Khawaja T, et al. Patients hospitalized abroad as importers of multiresistant bacteria—a cross-sectional study. *Clin Microbiol Infect* 2017 ; 23 : 673.e1-673.e8. PMID : 28196696
11. Hayakawa K, et al. High rate of multidrug-resistant organism colonization among patients hospitalized overseas highlights the need for preemptive infection control. *Am J Infect Control* 2016 ; 44 : e257-9. PMID : 27810070
12. Iovleva A, et al. Carbapenem-Resistant Enterobacteriaceae. *Clin Lab Med* 2017 ; 37 : 303-15. PMID : 28457352
13. Miller WR, et al. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases (English Edition) 9th ed. Philadelphia : Elsevier, 2019 : 2498.

5-10 ステロイド長期使用患者への対応 : 総論

◎参照文献

1. Duru N, et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. *Ann Rheum Dis* 2013 ; 72 : 1905-13. PMID : 23873876

2. Strehl C, et al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations : viewpoints from an EULAR task force. *Ann Rheum Dis* 2016 ; 75 : 952-7.
PMID : 26933146
3. Gurwitz JH, et al. Glucocorticoids and the risk for initiation of hypoglycemic therapy. *Arch Intern Med* 1994 ; 154 : 97-101.
PMID : 8267494
4. Hwang JL, et al. Steroid-induced diabetes : a clinical and molecular approach to understanding and treatment. *Diabetes Metab Res Rev* 2014 ; 30 : 96-102.
PMID : 24123849
5. Hricik DE, et al. Effects of steroid withdrawal on posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients. *Transplantation* 1991 ; 51 : 374-7.
PMID : 1994531
6. Dhataria K, et al. Management of Diabetes and Hyperglycemia in Hospitalized Patients. In : *Endotext* [Internet] . South Dartmouth (MA) : MDText.com, Inc. : 2000-. 2020 Dec 30.
PMID : 25905318
7. Kwon S, et al. Glucocorticoid-induced hyperglycemia. *Am J Med Sci* 2013 ; 345 : 274-7.
PMID : 23531958
8. Perez A, et al. Glucocorticoid-induced hyperglycemia. *J Diabetes* 2014 ; 6 : 9-20.
PMID : 24103089
9. American Diabetes Association. 6. Glycemic Targets : Standards of Medical Care in Diabetes-2018. *Diabetes Care* 2018 ; 41 : S55-64.
PMID : 29222377
10. American Diabetes Association. 14. Diabetes Care in the Hospital : Standards of Medical Care in Diabetes-2018. *Diabetes Care* 2018 ; 41 : S144-51. PMID : 29222385
11. Wallace MD, et al. Optimizing the Treatment of Steroid-Induced Hyperglycemia. *Ann Pharmacother* 2018 ; 52 : 86-90.
PMID : 28836444
12. Brady V, et al. Safe and effective dosing of basal-bolus insulin in patients receiving high-dose steroids for hyper-cyclophosphamide, doxorubicin, vincristine, and dexamethasone chemotherapy. *Diabetes Technol Ther* 2014 ; 16 : 874-9. PMID : 25321387
13. Fu Y, et al. Mineralocorticoid-induced sodium appetite and renal salt retention : evidence for common signaling and effector mechanisms. *Nephron Physiol* 2014 ; 128 : 8-16.
PMID : 25376899
14. Magill SB. Pathophysiology, diagnosis, and treatment of mineralocorticoid disorders. *Compr Physiol* 2014 ; 4 : 1083-119.
PMID : 24944031
15. Schrier RW. Aldosterone 'escape' vs 'breakthrough'. *Nat Rev Nephrol* 2010 ; 6 : 61.
PMID : 20111044
16. Young WF. Endocrine Hypertension. *Williams Textbook of Endocrinology*, 16, 542-72.e7
17. Huscher D, et al. Dose-related patterns of glucocorticoid-induced side effects. *Ann Rheum Dis* 2009 ; 68 : 1119-24.
PMID : 18684744
18. Panoulas VF, et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. *Rheumatology (Oxford)* 2008 ; 47 : 72-5.
PMID : 18077493
19. Goodwin JE, et al. Glucocorticoid-induced hypertension. *Pediatr Nephrol* 2012 ; 27 : 1059-66.
PMID : 21744056
20. Whitworth JA, et al. Glucocorticoid-induced hypertension : from mouse to man. *Clin*

- Exp Pharmacol Physiol 2001 ; 28 : 993-6. PMID : 11903301
21. Williamson PM, et al. Dose-response relationships and mineralocorticoid activity in cortisol-induced hypertension in humans. *J Hypertens Suppl* 1996 ; 14 : S37-41. PMID : 9120683
 22. Wei L, et al. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. *Ann Intern Med* 2004 ; 141 : 764-70. PMID : 15545676
 23. Wolfe F, et al. The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis : a cohort and nested case-control analysis. *Arthritis Rheum* 2008 ; 58 : 2612-21. PMID : 18759273
 24. Aviña-Zubieta JA, et al. Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis : a population-based study. *Rheumatology (Oxford)* 2013 ; 52 : 68-75. PMID : 23192907
 25. Ajeganova S, et al. Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival : 10-year follow-up of a 2-year randomised trial. *BMJ Open* 2014 ; 4 : e004259. PMID : 24710131
 26. Agca R, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders : 2015/2016 update. *Ann Rheum Dis* 2017 ; 76 : 17-28. PMID : 27697765
 27. Sovereign PC, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. *Heart* 2004 ; 90 : 859-65. PMID : 15253953
 28. van der Hooft CS, et al. Corticosteroids and the risk of atrial fibrillation. *Arch Intern Med* 2006 ; 166 : 1016-20. PMID : 16682576
 29. Christiansen CF, et al. Glucocorticoid use and risk of atrial fibrillation or flutter : a population-based, case-control study. *Arch Intern Med* 2009 ; 169 : 1677-83. PMID : 19822824
 30. MacGregor AJ, et al. Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus. *Ann Rheum Dis* 1992 ; 51 : 152-5. PMID : 1550394
 31. Pelletier AL, et al. Vision Loss in Older Adults. *Am Fam Physician* 2016 ; 94 : 219-26. PMID : 27479624
 32. Abdelkader H, et al. Age-related cataract and drug therapy : opportunities and challenges for topical antioxidant delivery to the lens. *J Pharm Pharmacol* 2015 ; 67 : 537-50. PMID : 25643848
 33. Da Silva JAP, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis : published evidence and prospective trial data. *Ann Rheum Dis* 2006 ; 65 : 285-93. PMID : 16107513
 34. Razeghinejad MR, et al. Steroid-induced iatrogenic glaucoma. *Ophthalmic Res* 2012 ; 47 : 66-80. PMID : 21757964
 35. Akingbehin AO. Corticosteroid-induced ocular hypertension. I. Prevalence in closed-angle glaucoma. *Br J Ophthalmol* 1982 ; 66 : 536-40. PMID : 7104271
 36. Piper JM, et al. Corticosteroid use and peptic ulcer disease : role of nonsteroidal anti-inflammatory drugs. *Ann Intern Med* 1991 ; 114 : 735-40. PMID : 2012355
 37. Hernández-Díaz S, et al. Steroids and risk of upper gastrointestinal complications. *Am J Epidemiol* 2001 ; 153 : 1089-93. PMID : 11390328

38. Garcia Rodríguez LA, et al. The risk of upper gastrointestinal complications associated with nonsteroidal anti-inflammatory drugs, glucocorticoids, acetaminophen, and combinations of these agents. *Arthritis Res* 2001 ; 3 : 98-101. PMID : 11178116
39. Yeomans ND, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. *Acid Suppression Trial : Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med* 1998 ; 338 : 719-26. PMID : 9494148
40. Agrawal NM, et al. Superiority of lansoprazole vs ranitidine in healing nonsteroidal anti-inflammatory drug-associated gastric ulcers : results of a double-blind, randomized, multicenter study. *NSAID-Associated Gastric Ulcer Study Group. Arch Intern Med* 2000 ; 160 : 1455-61. PMID : 10826458
41. Rostom A, et al. Prevention of NSAID-induced gastroduodenal ulcers. *Cochrane Database Syst Rev* 2002 ; (4) : CD002296. PMID : 12519573
42. Yuan JQ, et al. Systematic review with network meta-analysis : comparative effectiveness and safety of strategies for preventing NSAID-associated gastrointestinal toxicity. *Aliment Pharmacol Ther* 2016 ; 43 : 1262-75. PMID : 27121479
43. Pereira RMR, et al. Glucocorticoid-induced myopathy. *Joint Bone Spine* 2011 ; 78 : 41-4. PMID : 20471889
44. Caplan A, et al. Prevention and management of glucocorticoid-induced side effects : A comprehensive review : Ocular, cardiovascular, muscular, and psychiatric side effects and issues unique to pediatric patients. *J Am Acad Dermatol* 2017 ; 76 : 201-7. PMID : 28088991
45. Bowyer SL, et al. Steroid myopathy : incidence and detection in a population with asthma. *J Allergy Clin Immunol* 1985 ; 76 : 234-42. PMID : 4019954
46. 下畑享良ほか. % クレアチン尿の有用性の再検討. *脳と神経* 2006 ; 58 : 39-42.
47. Cooper MS, et al. Corticosteroid insufficiency in acutely ill patients. *N Engl J Med* 2003 ; 348 : 727-34. PMID : 12594318
48. Schlaghecke R, et al. The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone. *N Engl J Med* 1992 ; 326 : 226-30. PMID : 1309389
49. Ackerman GL, et al. Adrenocortical responsiveness after alternate-day corticosteroid therapy. *N Engl J Med* 1968 ; 278 : 405-9. PMID : 5636662
50. Coursin DB, et al. Corticosteroid supplementation for adrenal insufficiency. *JAMA* 2002 ; 287 : 236-40. PMID : 11779267
51. Aranow C, et al. Clinically occult avascular necrosis of the hip in systemic lupus erythematosus. *J Rheumatol* 1997 ; 24 : 2318-22. PMID : 9415635
52. Weldon D. The effects of corticosteroids on bone : osteonecrosis (avascular necrosis of the bone). *Ann Allergy Asthma Immunol* 2009 ; 103 : 91-7 ; quiz 97-100, 133. PMID : 19739420
53. Grossman JM. Lupus arthritis. *Best Pract Res Clin Rheumatol* 2009 ; 23 : 495-506. PMID : 19591780
54. Zalavras CG, et al. Osteonecrosis of the femoral head : evaluation and treatment. *J Am Acad Orthop Surg* 2014 ; 22 : 455-64. PMID : 24966252
55. Lai KA, et al. The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study. *J Bone*

- Joint Surg Am 2005 ; 87 : 2155-9. PMID : 16203877
56. Chen CH, et al. Alendronate in the prevention of collapse of the femoral head in nontraumatic osteonecrosis : a two-year multicenter, prospective, randomized, double-blind, placebo-controlled study. *Arthritis Rheum* 2012 ; 64 : 1572-8. PMID : 22127729
57. Hong YC, et al. Efficacy of alendronate for preventing collapse of femoral head in adult patients with nontraumatic osteonecrosis. *Biomed Res Int* 2014 ; 2014 : 716538. PMID : 25535614
58. Arai R, et al. Efficacy of teriparatide in the treatment of nontraumatic osteonecrosis of the femoral head : a retrospective comparative study with alendronate. *BMC Musculoskelet Disord* 2017 ; 18 : 24. PMID : 28103867
59. Agarwala S, et al. The use of alendronate in the treatment of avascular necrosis of the femoral head : follow-up to eight years. *J Bone Joint Surg Br* 2009 ; 91 : 1013-8. PMID : 19651826
60. Kazandjieva J, et al. Drug-induced acne. *Clin Dermatol* 2017 ; 35 : 156-62. PMID : 28274352
61. Da Silva JAP, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis : published evidence and prospective trial data. *Ann Rheum Dis* 2006 ; 65 : 285-93. PMID : 16107513
62. Costello R, et al. Patient perceptions of glucocorticoid side effects : a cross-sectional survey of users in an online health community. *BMJ Open* 2017 ; 7 : e014603. PMID : 28373256
63. Fardet L, et al. Suicidal behavior and severe neuropsychiatric disorders following glucocorticoid therapy in primary care. *Am J Psychiatry* 2012 ; 169 : 491-7. PMID : 22764363
64. Kenna HA, et al. Psychiatric complications of treatment with corticosteroids : review with case report. *Psychiatry Clin Neurosci* 2011 ; 65 : 549-60. PMID : 22003987
65. Dubovsky AN, et al. The neuropsychiatric complications of glucocorticoid use : steroid psychosis revisited. *Psychosomatics* 2012 ; 53 : 103-15. PMID : 22424158

5-11 ステロイド長期使用患者への対応 : 各論

◎ 参考文献

1. Nishikawa H, et al. Clinical significance of occult hepatitis B infection in progression of liver disease and carcinogenesis. *J Cancer* 2013 ; 4 : 473-80. PMID : 23901347
2. Terrault NA, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B : AASLD 2018 hepatitis B guidance. *Hepatology* 2018 ; 67 : 1560-99. PMID : 29405329
3. Oketani M, et al. Etiology and prognosis of fulminant hepatitis and late-onset hepatic failure in Japan : Summary of the annual nationwide survey between 2004 and 2009. *Hepatol Res* 2013 ; 43 : 97-105. PMID : 23409848
4. Umemura T, et al. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. *Clin Infect Dis* 2008 ; 47 : e52-6. PMID : 18643758
5. Alvarez-Suárez B, et al. Hepatitis B reactivation and current clinical impact. *Rev*

Esp Enferm Dig 2010 ; 102 : 542-52.

PMID : 20883071

6. 日本肝臓学会 肝炎診療ガイドライン作成委員会. B型肝炎治療ガイドライン (第3.3版). 2021年1月.<https://www.jsh.or.jp/medical/guidelines/jsh_guidlines/hepatitis_b.html>
7. 日本リウマチ学会. B型肝炎ウイルス感染リウマチ性疾患患者への免疫抑制療法に関する提言 (第4版改訂版). 2014年4月23日改訂.<<https://www.ryumachi-jp.com/info/news140423.pdf>>
8. Nair PV, et al. Effects of short-term, high-dose prednisone treatment of patients with HBsAg-positive chronic active hepatitis. Liver 1985 ; 5 : 8-12. PMID : 388495
9. Perrillo RP, et al. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015 ; 148 : 221-44.e3. PMID : 25447852
10. Reddy KR, et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015 ; 148 : 215-9 ; quiz e16-7. PMID : 25447850 **ガイドライン**
11. Schillie S, et al. Prevention of Hepatitis B Virus Infection in the United States : Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2018 ; 67 : 1-31. PMID : 29939980
12. Abara WE, et al. Hepatitis B Vaccination, Screening, and Linkage to Care : Best Practice Advice From the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med 2017 ; 167 : 794-804. PMID : 29159414
13. Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. Japan Society of Hepatology Guidelines for the Management of Hepatitis B Virus Infection : 2019 update. Hepatol Res 2020 ; 50 : 892-923. PMID : 32343469 **ガイドライン**
14. Ainoda Y, et al. Analysis of clinical features of non-HIV Pneumocystis jirovecii pneumonia. J Infect Chemother 2012 ; 18 : 722-8. PMID : 22460829
15. Tasaka S, et al. Recent advances in the diagnosis of Pneumocystis jirovecii pneumonia in HIV-infected adults. Expert Opin Med Diagn 2013 ; 7 : 85-97. PMID : 23530845
16. Thomas Jr CF, et al. Pneumocystis pneumonia. N Engl J Med 2004 ; 350 : 2487-98. PMID : 15190141
17. Stern A, et al. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 2014 ; 2014 : CD005590. PMID : 25269391
18. 箕輪健太郎ほか. ニューモシスチス肺炎の予防基準の有用性に関する検討. 日臨免疫会誌 2009 ; 32 : 256-62.
19. Kovacs JA, et al. Evolving health effects of Pneumocystis : one hundred years of progress in diagnosis and treatment. JAMA 2009 ; 301 : 2578-85. PMID : 19549975
20. Rodriguez M, et al. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev 2004 ; 17 : 770-82. PMID : 15489347
21. Limper AH, et al. An official American Thoracic Society statement : Treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit

- Care Med 2011 ; 183 : 96-128. PMID : 21193785
22. Kadoya A, et al. Risk factors for *Pneumocystis carinii* pneumonia in patients with polymyositis/dermatomyositis or systemic lupus erythematosus. J Rheumatol 1996 ; 23 : 1186-8. PMID : 8823690
 23. Meuli K, et al. Audit of pneumocystis pneumonia in patients seen by the Christchurch Hospital rheumatology service over a 5-year period. Intern Med J 2007 ; 37 : 687-92. PMID : 17517083
 24. White ES, et al. Pharmacological therapy for Wegener's granulomatosis. Drugs 2006 ; 66 : 1209-28. PMID : 16827598
 25. Ognibene FP, et al. *Pneumocystis carinii* pneumonia : a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis. Am J Respir Crit Care Med 1995 ; 151 : 795-9. PMID : 7881673
 26. Sepkowitz KA. Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome. Clin Infect Dis 2002 ; 34 : 1098-107. PMID : 11914999
 27. Godeau B, et al. *Pneumocystis carinii* pneumonia in the course of connective tissue disease : report of 34 cases. J Rheumatol 1994 ; 21 : 246-51. PMID : 8182632
 28. Harigai M, et al. Pneumocystis pneumonia associated with infliximab in Japan. N Engl J Med 2007 ; 357 : 1874-6. PMID : 17978303
 29. Mansharamani NG, et al. Peripheral blood CD4+ T-lymphocyte counts during *Pneumocystis carinii* pneumonia in immunocompromised patients without HIV infection. Chest 2000 ; 118 : 712-20. PMID : 10988193
 30. Green H, et al. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients : systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 2007 ; 82 : 1052-9. PMID : 17803871
 31. Di Cocco P, et al. A systematic review of two different trimethoprim-sulfamethoxazole regimens used to prevent *Pneumocystis jirovecii* and no prophylaxis at all in transplant recipients : appraising the evidence. Transplant Proc 2009 ; 41 : 1201-3. PMID : 19460516
 32. IDSA. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. <<https://www.idsociety.org/practice-guideline/prevention-and-treatment-of-opportunistic-infections-among-adults-and-adolescents/>>
- ガイドライン**
33. Park JW, et al. Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Ann Rheum Dis 2018 ; 77 : 644-9. PMID : 29092853
 34. Leoung GS, et al. Trimethoprim-sulfamethoxazole (TMP-SMZ) dose escalation versus direct rechallenge for *Pneumocystis carinii* pneumonia prophylaxis in human immunodeficiency virus-infected patients with previous adverse reaction to TMP-SMZ. J Infect Dis 2001 ; 184 : 992-7. PMID : 11574913
 35. Takenaka K, et al. A dose-escalation regimen of trimethoprim-sulfamethoxazole is tolerable for prophylaxis against *Pneumocystis jirovecii* pneumonia in rheumatic diseases. Mod Rheumatol 2013 ; 23 : 752-8. PMID : 22907597
 36. Suyama Y, et al. Safety and efficacy of upfront graded administration of trimethoprim-sulfamethoxazole in systemic lupus erythematosus : A retrospective cohort

- study. *Mod Rheumatol* 2016 ; 26 : 557-61. PMID : 26587755
37. Maezawa R, et al. Positivity for anti-RNP antibody is a risk factor for adverse effects caused by trimethoprim-sulfamethoxazole, a prophylactic agent for *P. jirovecii* pneumonia, in patients with connective tissue diseases. *Mod Rheumatol* 2013 ; 23 : 62-70. PMID : 22466117
38. Bozzette SA, et al. A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. *N Engl J Med* 1995 ; 332 : 693-9. PMID : 7854375
39. Lewinsohn DM, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines : Diagnosis of Tuberculosis in Adults and Children. *Clin Infect Dis* 2017 ; 64 : e1-33. PMID : 27932390 **ガイドライン**
40. CDC. Latent TB Infection testing+ treatment. summary of U.S. recommendations. June 2020. <<https://www.cdc.gov/tb/publications/lbti/pdf/CDC-USPSTF-LTBI-Testing-Treatment-Recommendations-508.pdf>>
41. WHO. Latent TB Infection : Updated and consolidated guidelines for programmatic management. 2018. <<https://www.who.int/tb/publications/2018/latent-tuberculosis-infection/en/>> **ガイドライン**
42. Prevention Committee of the Japanese Society for Tuberculosis ; Treatment Committee of the Japanese Society for Tuberculosis. Treatment guidelines for latent tuberculosis infection. *Kekkaku* 2014 ; 89 : 21-37. PMID : 24654427 **ガイドライン**
43. Horsburgh Jr CR, et al. Clinical practice. Latent tuberculosis infection in the United States. *N Engl J Med* 2011 ; 364 : 1441-8. PMID : 21488766
44. Jick SS, et al. Glucocorticoid use, other associated factors, and the risk of tuberculosis. *Arthritis Rheum* 2006 ; 55 : 19-26. PMID : 16463407
45. Pai M, et al. Systematic review : T-cell-based assays for the diagnosis of latent tuberculosis infection : an update. *Ann Intern Med* 2008 ; 149 : 177-84. PMID : 18593687
46. Sharninghausen JC, et al. Risk Factors for Indeterminate Outcome on Interferon Gamma Release Assay in Non-US-Born Persons Screened for Latent Tuberculosis Infection. *Open Forum Infect Dis* 2018 ; 5 : ofy184. PMID : 30151410
47. Powell 3rd RD, et al. Unusual interferon gamma measurements with QuantiFERON-TB Gold and QuantiFERON-TB Gold In-Tube tests. *PLoS One* 2011 ; 6 : e20061. PMID : 21687702
48. Hartman-Adams H, et al. Update on latent tuberculosis infection. *Am Fam Physician* 2014 ; 89 : 889-96. PMID : 25077395
49. Mazurek GH, et al. Updated guidelines for using Interferon Gamma Release Assays to detect *Mycobacterium tuberculosis* infection — United States, 2010. *MMWR Recomm Rep* 2010 ; 59 : 1-25. PMID : 20577159 **ガイドライン**
50. 日本結核病学会予防委員会. 今後のツベルクリン反応検査の暫定的技術的基準. *結核* 2006 ; 81 : 387-91.
51. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA),

- September 1999, and the sections of this statement. *Am J Respir Crit Care Med* 2000 ; 161 : S221-47. PMID : 10764341
52. Stagg HR, et al. Treatment of latent tuberculosis infection : a network meta-analysis. *Ann Intern Med* 2014 ; 161 : 419-28. PMID : 25111745
53. Nahid P, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines : Treatment of Drug-Susceptible Tuberculosis. *Clin Infect Dis* 2016 ; 63 : e147-95. PMID : 27516382 **ガイドライン**
54. Buckley L, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. *Arthritis Rheumatol* 2017 ; 69 : 1521-37. PMID : 28585373 **ガイドライン**
55. Suzuki Y, et al. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research : 2014 update. *J Bone Miner Metab* 2014 ; 32 : 337-50. PMID : 24818875 **ガイドライン**
56. Curtis JR, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. *Arthritis Rheum* 2006 ; 55 : 420-6. PMID : 16739208
57. Canalis E, et al. Glucocorticoid-induced osteoporosis : pathophysiology and therapy. *Osteoporos Int* 2007 ; 18 : 1319-28. PMID : 17566815
58. Angeli A, et al. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy : a cross-sectional outpatient study. *Bone* 2006 ; 39 : 253-9. PMID : 16574519
59. Van Staa TP, et al. Use of oral corticosteroids and risk of fractures. *J Bone Miner Res* 2000 ; 15 : 993-1000. PMID : 10841167
60. Van Staa TP, et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. *Arthritis Rheum* 2003 ; 48 : 3224-9. PMID : 14613287
61. LoCascio V, et al. Bone loss in response to long-term glucocorticoid therapy. *Bone Miner* 1990 ; 8 : 39-51. PMID : 2306553
62. Weinstein RS. Clinical practice. Glucocorticoid-induced bone disease. *N Engl J Med* 2011 ; 365 : 62-70. PMID : 21732837
63. Laan RF, et al. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. *Ann Intern Med* 1993 ; 119 : 963-8. PMID : 8105737
64. Hall GM, et al. The effect of rheumatoid arthritis and steroid therapy on bone density in postmenopausal women. *Arthritis Rheum* 1993 ; 36 : 1510-6. PMID : 8240428
65. FRAX[®] : Fracture Risk Assessment Tool <<https://www.sheffield.ac.uk/FRAX/tool.aspx?country=3>>
66. Lekamwasam S, et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. *Osteoporos Int* 2012 ; 23 : 2257-76. PMID : 22434203 **ガイドライン**
67. Cosman F, et al. Clinician's Guide to Prevention and Treatment of Osteoporosis. *Osteoporos Int* 2014 ; 25 : 2359-81. PMID : 25182228
68. The International Society For Clinical Densitometry (ISCD) Official Positions — Adult. 2019. <<https://iscd.org/learn/official-positions/adult-positions/>>
69. 骨粗鬆症の予防と治療ガイドライン作成委員会. 骨粗鬆症の予防と治療ガイドライン

- 2015年版. <<http://jsbmr.umin.jp/pdf/GL2015.pdf>>
70. 厚生労働省. 平成29年国民健康・栄養調査結果の概要<<https://www.mhlw.go.jp/content/10904750/000351576.pdf>>
 71. Richey F, et al. Efficacy of alfacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. *Osteoporos Int* 2004; 15: 301-10. PMID: 14740153
 72. Matsumoto T, et al. A new active vitamin D₃ analog, eldecalcitol, prevents the risk of osteoporotic fractures — a randomized, active comparator, double-blind study. *Bone* 2011; 49: 605-12. PMID: 21784190
 73. Nakamura T, et al. Eldecalcitol is more effective for the prevention of osteoporotic fractures than alfacalcidol. *J Bone Miner Metab* 2013; 31: 417-22. PMID: 23575909
 74. Saag KG, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. *Arthritis Rheum* 2009; 60: 3346-55. PMID: 19877063
 75. Mandema JW, et al. Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response-based meta-analysis. *J Clin Endocrinol Metab* 2014; 99: 3746-55. PMID: 24915115
 76. Migliore A, et al. Ranking antireabsorptive agents to prevent vertebral fractures in postmenopausal osteoporosis by mixed treatment comparison meta-analysis. *Eur Rev Med Pharmacol Sci* 2013; 17: 658-67. PMID: 23543450
 77. Zhou Z, et al. Safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysis. *Int J Clin Exp Pathol* 2014; 7: 2113-22. PMID: 24966919
 78. Freemantle N, et al. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. *Osteoporos Int* 2012; 23: 317-26. PMID: 21927922
 79. 日本口腔外科学会. 骨吸収抑制薬関連顎骨壊死の病態と管理: 顎骨壊死検討委員会ポジションペーパー 2016. <<https://www.jsoms.or.jp/medical/work/guideline/bisphos01/>>
 80. Khan AA, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. *J Bone Miner Res* 2015; 30: 3-23. PMID: 25414052
 81. Compston J, et al. UK clinical guideline for the prevention and treatment of osteoporosis. *Arch Osteoporos* 2017; 12: 43. PMID: 28425085 **ガイドライン**
 82. Ruggiero SL, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw — 2014 update. *J Oral Maxillofac Surg* 2014; 72: 1938-56. PMID: 25234529
 83. Shane E, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. *J Bone Miner Res* 2014; 29: 1-23. PMID: 23712442
 84. Lee S, et al. Increased risk for atypical fractures associated with bisphosphonate use. *Fam Pract* 2015; 32: 276-81. PMID: 25846215

5-12 免疫抑制薬・生物学的製剤使用中の入院

◎参照文献

1. Harigai M. Lymphoproliferative disorders in patients with rheumatoid arthritis in the era of widespread use of methotrexate : A review of the literature and current perspective. *Mod Rheumatol* 2018 ; 28 : 1-8. PMID : 28758827
2. Annane D, et al. Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I) : Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. *Intensive Care Med* 2017 ; 43 : 1751-63. PMID : 28940011 **ガイドライン**
3. Honda S, et al. Management of End-stage Renal Disease Associated with Systemic Rheumatic Diseases. *JMA J* 2020 ; 3 : 20-8. PMID : 33324772
4. 近藤峰生ほか. ヒドロキシクロロキン適正使用のための手引き. *日眼会誌* 2016 ; 120 : 419-28. <<http://www.nichigan.or.jp/member/guideline/hydroxychloroquine.pdf>> **ガイドライン**
5. Sharma AN, et al. Characterizing the adverse dermatologic effects of hydroxychloroquine : A systematic review. *J Am Acad Dermatol* 2020 ; 83 : 563-78. PMID : 32289395
6. 陶山恭博ほか. ステロイドを内服している人が ER にやってきたら. *J-COSMO* 2019 ; 1 : 26-35.
7. Sarrecchia C, et al. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. *J Infect Chemother* 2005 ; 11 : 189-91. PMID : 16133710
8. Nash P, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors : a consensus statement. *Ann Rheum Dis* 2021 ; 80 : 71-87. PMID : 33158881
9. Goodman SM, et al. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. *Arthritis Rheumatol* 2017 ; 69 : 1538-51. PMID : 28620948 **ガイドライン**

5-13 免疫抑制薬・生物学的製剤使用中の発熱

◎参照文献

1. Edgar JDM. T cell immunodeficiency. *J Clin Pathol* 2008 ; 61 : 988-93. PMID : 18755723
2. 青木 眞. レジデントのための感染症診療マニュアル第4版. 東京 : 医学書院, 2020.
3. Di Bisceglie AM, et al. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs : just the tip of the iceberg? *Hepatology* 2015 ; 61 : 703-11. PMID : 25412906
4. Winthrop KL, et al. Herpes Zoster and Tofacitinib : Clinical Outcomes and the Risk of Concomitant Therapy. *Arthritis Rheumatol* 2017 ; 69 : 1960-8. PMID : 28845604
5. Molloy ES, et al. Progressive multifocal leukoencephalopathy associated with immu-

- nosuppressive therapy in rheumatic diseases : evolving role of biologic therapies. *Arthritis Rheum* 2012 ; 64 : 3043-51. PMID : 22422012
6. Hughes WT, et al. Successful intermittent chemoprophylaxis for *Pneumocystis carinii* pneumonitis. *N Engl J Med* 1987 ; 316 : 1627-32. PMID : 3495732
 7. Dixon WG, et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis : a nested case-control analysis. *Ann Rheum Dis* 2012 ; 71 : 1128-33. PMID : 22241902
 8. Bari SF, et al. C reactive protein may not be reliable as a marker of severe bacterial infection in patients receiving tocilizumab. *BMJ Case Rep* 2013 ; 2013 : bcr2013010423. PMID : 24177456
 9. Wang JY, et al. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. *Thorax* 2006 ; 61 : 903-8. PMID : 16809417
 10. Ding LW, et al. Disease caused by non-tuberculous mycobacteria in a university hospital in Taiwan, 1997-2003. *Epidemiol Infect* 2006 ; 134 : 1060-7. PMID : 16492317
 11. Winthrop KL, et al. Nontuberculous mycobacteria infections and anti-tumor necrosis factor- α therapy. *Emerg Infect Dis* 2009 ; 15 : 1556-61. PMID : 19861045
 12. Winthrop KL, et al. Bedfellows : mycobacteria and rheumatoid arthritis in the era of biologic therapy. *Nat Rev Rheumatol* 2013 ; 9 : 524-31. PMID : 23797309
 13. 日本肝臓学会 肝炎診療ガイドライン作成委員会. B型肝炎治療ガイドライン (第3.3版). 2021年1月.<https://www.jsh.or.jp/medical/guidelines/jsh_guidlines/hepatitis_b.html> **ガイドライン**

● 推奨文献

- Fernández-Ruiz M, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies : an infectious diseases perspective (Introduction). *Clin Microbiol Infect* 2018 ; 24 Suppl 2 : S2-9. PMID : 29427801
- Baddley JW, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies : an infectious diseases perspective (Soluble immune effector molecules [I] : anti-tumor necrosis factor- α agents). *Clin Microbiol Infect* 2018 ; 24 Suppl 2 : S10-20. PMID : 29459143
- Aguilar-Company J, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies : an infectious diseases perspective (Cell surface receptors and associated signaling pathways). *Clin Microbiol Infect* 2018 ; 24 Suppl 2 : S41-52. PMID : 29426804
- Reinwald M, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies : an infectious diseases perspective (Intracellular signaling pathways : tyrosine kinase and mTOR inhibitors). *Clin Microbiol Infect* 2018 ; 24 Suppl 2 : S53-70. PMID : 29454849
- Mikulska M, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies : an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I] : CD19, CD20 and CD52). *Clin Microbiol Infect* 2018 ; 24 Suppl 2 : S71-82.

PMID : 29447988

- Drgona L, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies : an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II] : CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4). Clin Microbiol Infect 2018 ; 24 Suppl 2 : S83-94. PMID : 29572070
- Redelman-Sidi G, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies : an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors). Clin Microbiol Infect 2018 ; 24 Suppl 2 : S95-107. PMID : 29427804
- 大曲貴夫ほか編. 免疫不全者の呼吸器感染症. 東京 : 南山堂, 2011.
- 青柳有紀ほか訳. チャンドラセカール 移植・免疫不全者の感染症. 東京 : メディカル・サイエンス・インターナショナル, 2017.

5-14 免疫不全患者のワクチン

◎ 参考文献

1. Rubin LG, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014 ; 58 : 309-18. PMID : 24421306 **ガイドライン**
2. 日本造血細胞移植学会ガイドライン委員会. 造血細胞移植学会ガイドライン 第1巻. 東京 : 医薬ジャーナル社, 2014 : 162-208. **ガイドライン**
3. Namkoong H, et al. Comparison of the immunogenicity and safety of polysaccharide and protein-conjugated pneumococcal vaccines among the elderly aged 80 years or older in Japan : an open-labeled randomized study. Vaccine 2015 ; 33 : 327-32. PMID : 25448102
4. Jackson LA, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2013 ; 31 : 3585-93. PMID : 23688527
5. Greenberg RN, et al. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naïve adults 60-64 years of age. Vaccine 2014 ; 32 : 2364-74. PMID : 24606865
6. Kim DK, et al. Recommended Immunization Schedule for Adults Aged 19 Years or Older, United States, 2018. Ann Intern Med 2018 ; 168 : 210-20. PMID : 29404596
7. Di Sabatino A, et al. Post-splenectomy and hyposplenic states. Lancet 2011 ; 378 : 86-97. PMID : 21474172
8. Kyaw MH, et al. Evaluation of severe infection and survival after splenectomy. Am J Med 2006 ; 119 : 276.e1-7. PMID : 16490477

5-15 膠原病関連疾患の自己抗体

◎ 参考文献

1. Mariz HA, et al. Pattern on the antinuclear antibody-HEp-2 test is a critical param-

eter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. *Arthritis Rheum* 2011 ; 63 : 191-200.

PMID : 20954189

2. Tan EM, et al. Range of antinuclear antibodies in "healthy" individuals. *Arthritis Rheum* 1997 ; 40 : 1601-11.

PMID : 9324014

● 推奨文献

- 陶山恭博ほか. 膠原病関連自己抗体. *総合診療* 2019 ; 29 : 911-5.